A
Amaia Lujambio
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 90
Citations - 7684
Amaia Lujambio is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Cancer & Epigenetics. The author has an hindex of 26, co-authored 73 publications receiving 5892 citations. Previous affiliations of Amaia Lujambio include Cold Spring Harbor Laboratory & Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
A microRNA DNA methylation signature for human cancer metastasis
Amaia Lujambio,George A. Calin,Alberto Villanueva,Santiago Ropero,Montserrat Sanchez-Cespedes,David Blanco,Luis M. Montuenga,Simona Rossi,Milena S. Nicoloso,William J. Faller,William M. Gallagher,Suzanne A. Eccles,Carlo M. Croce,Manel Esteller +13 more
TL;DR: Findings indicate that DNA methylation-associated silencing of tumor suppressor miRNAs contributes to the development of human cancer metastasis.
Journal ArticleDOI
The microcosmos of cancer
TL;DR: The discovery of microRNAs almost two decades ago established a new paradigm of gene regulation, and during the past ten years these tiny non-coding RNAs have been linked to virtually all known physiological and pathological processes, including cancer.
Journal ArticleDOI
Genetic Unmasking of an Epigenetically Silenced microRNA in Human Cancer Cells
Amaia Lujambio,Santiago Ropero,Esteban Ballestar,Mario F. Fraga,Celia Cerrato,Fernando Setien,Sara Casado,Ana Suárez-Gauthier,Montserrat Sanchez-Cespedes,Anna Gitt,Inmaculada Spiteri,Partha Pratim Das,Carlos Caldas,Eric A. Miska,Manel Esteller +14 more
TL;DR: Interestingly, this work functionally link the epigenetic loss of miRNA-124a with the activation of cyclin D kinase 6, a bona fide oncogenic factor, and the phosphorylation of the retinoblastoma, a tumor suppressor gene.
Journal ArticleDOI
Non-Cell-Autonomous Tumor Suppression by p53
Amaia Lujambio,Leila Akkari,Janelle Simon,Janelle Simon,Janelle Simon,Danielle Grace,Danielle Grace,Darjus F. Tschaharganeh,Jessica E. Bolden,Jessica E. Bolden,Zhen Zhao,Zhen Zhao,Vishal Thapar,Vishal Thapar,Johanna A. Joyce,Valery Krizhanovsky,Valery Krizhanovsky,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe +19 more
TL;DR: The p53 tumor suppressor can restrict malignant transformation by triggering cell-autonomous programs of cell-cycle arrest or apoptosis as discussed by the authors, and also promotes cellular senescence, a tumor-suppressive program that involves stable cellcycle arrest and secretion of factors that modify the tissue microenvironment.
Journal ArticleDOI
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister,Dominik Pfister,Nicolás Gonzalo Núñez,Roser Pinyol,Olivier Govaere,Matthias Pinter,Marta Szydlowska,Revant Gupta,Mengjie Qiu,Aleksandra Deczkowska,Assaf Weiner,Florian Müller,Ankit Sinha,Ankit Sinha,Ekaterina Friebel,Thomas Engleitner,Thomas Engleitner,Daniela Lenggenhager,Anja Moncsek,Danijela Heide,Kristin Stirm,Jan Kosla,Eleni Kotsiliti,Valentina Leone,Michael Dudek,Suhail Yousuf,Donato Inverso,Donato Inverso,Indrabahadur Singh,Ana Teijeiro,Florian Castet,Carla Montironi,Philipp K. Haber,Dina Tiniakos,Dina Tiniakos,Pierre Bedossa,Simon Cockell,Ramy Younes,Ramy Younes,Michele Vacca,Fabio Marra,Jörn M. Schattenberg,Michael Allison,Elisabetta Bugianesi,Vlad Ratziu,Tiziana Pressiani,Antonio D'Alessio,Nicola Personeni,Lorenza Rimassa,Ann K. Daly,Bernhard Scheiner,Katharina Pomej,Martha M. Kirstein,Arndt Vogel,Markus Peck-Radosavljevic,F. Hucke,Fabian Finkelmeier,Oliver Waidmann,Jörg Trojan,Kornelius Schulze,Henning Wege,Sandra Koch,Arndt Weinmann,Marco Bueter,Fabian Rössler,Alexander Siebenhüner,Sara De Dosso,Jan-Philipp Mallm,Viktor Umansky,Viktor Umansky,Manfred Jugold,Tom Luedde,Andrea Schietinger,Andrea Schietinger,Peter Schirmacher,Brinda Emu,Hellmut G. Augustin,Hellmut G. Augustin,Adrian T. Billeter,Beat P. Müller-Stich,Hiroto Kikuchi,Dan G. Duda,Fabian Kütting,Dirk Waldschmidt,Matthias P. Ebert,Nuh N. Rahbari,Henrik E. Mei,Axel Schulz,Marc Ringelhan,Nisar P. Malek,Stephan Spahn,Michael Bitzer,Marina Ruiz de Galarreta,Amaia Lujambio,Jean-François Dufour,Thomas U. Marron,Thomas U. Marron,Ahmed Kaseb,Masatoshi Kudo,Yi Hsiang Huang,Yi Hsiang Huang,Nabil Djouder,Katharina Wolter,Lars Zender,Lars Zender,Parice N. Marche,Parice N. Marche,Thomas Decaens,Thomas Decaens,David J. Pinato,Roland Rad,Roland Rad,Joachim C. Mertens,Achim Weber,Kristian Unger,Felix Meissner,Susanne Roth,Zuzana Macek Jilkova,Zuzana Macek Jilkova,Zuzana Macek Jilkova,Manfred Claassen,Quentin M. Anstee,Ido Amit,Percy A. Knolle,Burkhard Becher,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Mathias Heikenwalder +128 more
TL;DR: The progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers provides a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.